Diabetes News and Research

Latest Diabetes News and Research

COGS receives $10 million renewal grant from National Institute of Mental Health

The six-site Consortium on the Genetics of Schizophrenia (COGS), led by the director of the Schizophrenia Program at the University of California, San Diego School of Medicine, has received a $10 million renewal grant from the National Institute of Mental Health (NIMH), one of the National Institutes of Health. The grant funds an ongoing, multiple-site collaboration examining the genetic architecture of the causes and abnormalities related to schizophrenia.

31 Jul 2010

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Jonathan Stamler, MD, Director of the Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University and University Hospitals Harrington-McLaughlin Heart & Vascular Institute, has recently received a $4.7 million contract from the Defense Advanced Research Projects Agency to fund the development of a new class of drugs that will selectively dilate blood cells under hypoxia (lack of oxygen in the body's tissues) and thereby enhance soldiers' performance at high altitude.

31 Jul 2010

Resveratrol suppresses inflammation in humans: Research

Resveratrol, a popular plant extract shown to prolong life in yeast and lower animals due to its anti-inflammatory and antioxidant properties, appears also to suppress inflammation in humans, based on results from the first prospective human trial of the extract conducted by University at Buffalo endocrinologists.

31 Jul 2010

Today's OpEds: Medicare at 45; The politics of entitlement spending; Deciding health care's value

Forty-five years ago today, the creation of Medicare transformed our health-care system and our nation. It helped to make us a stronger and more prosperous country by freeing older Americans from the fear that sickness or injury would cost them their lifetime savings and security. ... The reason we have the Medicare we have today is that over the last 45 years, we have repeatedly acted to strengthen and update it for changing times (Kathleen Sebelius, 7/29).

31 Jul 2010

USIBC applauds Abbott for 100 years of improving healthcare in India

Today the U.S.-India Business Council (USIBC) saluted Abbott Laboratories for 100 years of improving healthcare in India. In 1910, Abbott was one of the first multinationals to establish operations in India. Over the past century, Abbott has been dedicated to connecting Indian patients with access to quality medication and patient care, enhancing the quality of life for its customers.

30 Jul 2010

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

Resveratrol suppresses inflammation and free radicals: Study

30 Jul 2010

New health reform law to benefit 30 million women: Commonwealth Fund report

Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. In the first analysis of its kind, the authors report that the law will stabilize and reverse the growing exposure to health costs that women now experience by subsidizing health insurance for up to 15 million currently uninsured women, and strengthening existing coverage for 14.5 million women who are considered underinsured-those who have health coverage that does not adequately protect them from high medical expenses.

30 Jul 2010

Actient Pharmaceuticals completes transaction to license, acquire pharmaceutical products from UCB

GTCR, one of the country's leading private equity firms, announced today that Actient Pharmaceuticals, LLC has successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an international biopharmaceutical company based in Brussels, Belgium.

30 Jul 2010

SynCo Bio Partners extends collaboration with Versartis

SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis' lead product VRS-859 (exenatide-XTEN).

30 Jul 2010

Nutrisystem second-quarter revenues increase 8% to $141.6 million

Nutrisystem, Inc., a leading provider of weight management products and services, today reported financial results for the second quarter of 2010.

30 Jul 2010

Study explores benefits, risks of aggressive blood sugar control in hemodialysis patients

Aggressive blood sugar control does not improve survival in diabetic patients with kidney failure, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest that physicians should individualize blood sugar targets for these patients and not rely on recommendations based on studies in the general population.

30 Jul 2010

Researchers discover tumor suppressor lincRNAs

The recent discovery of more than a thousand genes known as large intergenic non-coding RNAs (or "lincRNAs") opened up a new approach to understanding the function and organization of the genome. That surprising breakthrough is now made even more compelling with the finding that dozens of these lincRNAs are induced by p53 (the most commonly mutated gene in cancer), suggesting that this class of genes plays a critical role in cell development and regulation. Furthermore, the researchers identify one lincRNA in particular (lincRNA-p21), and demonstrate its critical role in suppressing the reading of many genes across the genome following p53 activation.

30 Jul 2010

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Bio-Path Holdings, Inc.,, a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS).

30 Jul 2010

Study on link between SNP and concentrations of serum creatinine

Scientists at deCODE genetics and colleagues at Radboud University in the Netherlands today describe how the impact of a single letter variation in the sequence of the human genome conferring risk of kidney disease varies with age and with the onset of other diseases. The study provides independent confirmation of the association made in an earlier study between a version of the the SNP, located on chromosome 16p12, and risk of chronic kidney disease. It also confirmed the link between the SNP and concentrations of serum creatinine, a key indicator of kidney function.

30 Jul 2010

Researchers find new pathway that leads to brain cell death in neurodegenerative disorders

Although their genetic underpinnings differ, Alzheimer's disease, Parkinson's disease and Huntington's disease are all characterized by the untimely death of brain cells. What triggers cell death in the brain? According to a new study published by researchers at Sanford-Burnham Medical Research Institute in the July 30 issue of Molecular Cell, the answer in some cases is the untimely transfer of a gaseous molecule (known as nitric oxide, or NO) from one protein to another.

30 Jul 2010

Researchers identify genetic mutation for Uner Tan Syndrome

A team of researchers from leading universities in Turkey and the United States have reported that they have identified the genetic mutation responsible for the Uner Tan Syndrome (UTS) using advanced genetic capture and sequencing technologies from Roche. The combined genomic technologies enabled the team of scientists to identify the causative mutation of this debilitating disease after years of mystery.

30 Jul 2010

Orexigen's Contrave COR-I trial results published online in journal Lancet

Orexigen® Therapeutics, Inc. announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.

30 Jul 2010

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.

30 Jul 2010

Diabetes News and Research

Latest Diabetes News and Research

COGS receives $10 million renewal grant from National Institute of Mental Health

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Resveratrol suppresses inflammation in humans: Research

Today's OpEds: Medicare at 45; The politics of entitlement spending; Deciding health care's value

USIBC applauds Abbott for 100 years of improving healthcare in India

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Resveratrol suppresses inflammation and free radicals: Study

New health reform law to benefit 30 million women: Commonwealth Fund report

Actient Pharmaceuticals completes transaction to license, acquire pharmaceutical products from UCB

SynCo Bio Partners extends collaboration with Versartis

Nutrisystem second-quarter revenues increase 8% to $141.6 million

Study explores benefits, risks of aggressive blood sugar control in hemodialysis patients

Researchers discover tumor suppressor lincRNAs

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Study on link between SNP and concentrations of serum creatinine

Researchers find new pathway that leads to brain cell death in neurodegenerative disorders

Researchers identify genetic mutation for Uner Tan Syndrome

Orexigen's Contrave COR-I trial results published online in journal Lancet

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Diabetes News and Research

Latest Diabetes News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in